## **BILL SUMMARY** 1<sup>st</sup> Session of the 59<sup>th</sup> Legislature

Bill No.:	HB 1713
Version:	Introduced
Request Number:	6690
Author:	Rep. Marti
Date:	2/27/2023
Impact: Please see previous summary of this measure	

## **Research Analysis**

HB 1713, as introduced, prohibits pharmaceutical drug plans and pharmacy benefit managers from refusing to authorize, approve, or pay a participating provider for supplying covered physician-administered drugs to patients and requires all white-bagged drugs to meet supply chain security controls. Plan providers are prohibited from requiring a patient to self-administer an injectable drug against a provider's recommendation and may not require patients to pay additional fees beyond cost-sharing obligations outlined in the individual's plan. The measure also requires that providers establish a billing method based on the patient's best interest. Any payer in violation is to be fined a minimum of \$5,000 but not more than \$10,000 per violation.

Prepared By: Matthew Brenchley

## **Fiscal Analysis**

The measure is currently under review and impact information will be completed.

Prepared By: House Fiscal Staff

## **Other Considerations**

None.

© 2021 Oklahoma House of Representatives, see Copyright Notice at www.okhouse.gov